Clinical applications of Gymnema sylvestre against type 2 diabetes mellitus and its associated abnormalities
Keywords:
Diabetes Mellitus, Gymnema sylvestre, Anti-diabetic, Anti-hyperlipidemic, Anti-inflammatory, Anti-CancerousAbstract
Diabetes mellitus (Madhumeha) is one of the leading metabolic disorder prevalent in the developing countries which is characterized by high blood sugar level and is associated with macrovascular and microvascular complications. The Indian Ayurveda describes several herbs for the management and treatment of diabetes mellitus among which Gymnema sylvestre (Asclepiadaceae) is revered as a potential antidiabetic herbal drug which has the capability of simultaneously regenerating β-cell and stimulating insulin secretion. Gymnema sylvestre also possesses anti-obesity, anti-hyperlipidemic, anti-inflammatory, and anti-cancerous activities. This review updates the recent developments in the experimental studies conducted on the Gymnema sylvestre as an effective remedy for diabetes mellitus evidenced by both animals and human studies. Moreover, this study also discussed the toxicity of Gymnema sylvestre and future challenges in the roadmap of formulation for prevention and control of diabetes.
Downloads
Published
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.